Liu Shaoyan, Ni Song, Zhu Yiming, Wang Jian
Department of Head and Neck Surgery, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China; Email:
Department of Head and Neck Surgery, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2015 May;37(5):392-4.
Myoepithelial carcinoma (MC) is a rare malignant neoplasm of the salivary gland. The aim of this study was to analyze the diagnosis, treatment and prognosis of MC of the parotid gland.
The clinicopathological data of 17 cases of MC of the parotid gland treated in our hospital from 1999 to 2013 were analyzed retrospectively. Of all the 17 patients, 9 cases received radical surgery only, 5 cases received postoperative radiotherapy, 2 cases received preoperative radiotherapy, and one case received chemotherapy. The survival rate was calculated by Kaplan-Meier analysis.
Among the 17 patients, 11 patients had post-operative recurrence (11/17, 64.7%), Of these 11 cases, 5 cases (45.5%) had recurrence within one year after the first operation. During the follow-up for 12-180 months (median 50 months), six cases died (two patients died of distant metastases and 4 cases died of local recurrence). The overall 1-year, 2-year and 5-year survival rates were 94.1%, 74.2% and 64.9%, and the overall 1-year, 2-year and 5-year recurrence-free survival rates were 70.6%, 48.1% and 40.1%, respectively.
Radical surgery is the main treatment modality for myoepithelial carcinoma of the parotid gland. For the patients with extensive lesions or after palliative surgery, adjuvant radiotherapy or chemotherapy might be helpful. However, its therapeutic efficacy remains to be proved.
肌上皮癌(MC)是一种罕见的涎腺恶性肿瘤。本研究旨在分析腮腺肌上皮癌的诊断、治疗及预后情况。
回顾性分析我院1999年至2013年收治的17例腮腺肌上皮癌患者的临床病理资料。17例患者中,9例仅接受根治性手术,5例接受术后放疗,2例接受术前放疗,1例接受化疗。采用Kaplan-Meier法计算生存率。
17例患者中,11例术后复发(11/17,64.7%),其中5例(45.5%)在首次手术后1年内复发。随访12 - 180个月(中位50个月),6例死亡(2例死于远处转移,4例死于局部复发)。1年、2年和5年总生存率分别为94.1%、74.2%和64.9%,1年、2年和5年无复发生存率分别为70.6%、48.1%和40.1%。
根治性手术是腮腺肌上皮癌的主要治疗方式。对于病变广泛或姑息性手术后的患者,辅助放疗或化疗可能有益。然而,其治疗效果仍有待证实。